Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01508312 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma

Interventions

DRUG: brentuximab vedotin (SGN-35)
DRUG: Brentuximab Vedotin (SGN-35)

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]